Literature DB >> 17379963

Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma.

Tae Sik Jung1, Tae Yong Kim, Kyung Won Kim, Young Lyun Oh, Do Joon Park, Bo Youn Cho, Young Kee Shong, Won Bae Kim, Young Joo Park, Jung Hwa Jung, Jae Hoon Chung.   

Abstract

We performed this study to compare the clinicopathologic features and outcomes between the patients with poorly differentiated thyroid carcinoma (PDTC) and the patients with the aggressive variants of papillary thyroid carcinoma (PTC). To evaluate the prognostic factors for survival of the patients with PDTC, we selected 49 patients with PDTC and 23 patients with the aggressive variants of PTC from three hospitals during the recent 15 years. The five-year survival rate and clinicopathologic features of the patients with PDTC were not different from those of the patients with the aggressive variants of PTC. Univariate analysis revealed the significant poor prognostic factors for survival of the patients with PDTC and the aggressive variants of PTC as follows: 1) an age more than 45 years, 2) a tumor size larger than 4 cm, 3) the presence of tumor invasion to extrathyroidal tissue or the trachea, 4) the presence of cervical lymph node invasion, 5) the presence of distant metastasis, 6) the absence of high-dose radioactive iodine (RAI) therapy, and 7) TNM stage II, III and IV. Distant metastasis and high-dose RAI therapy were independent significant predictors for survival of the patients with PDTC and the aggressive variants of PTC on multivariate analysis. However, distant metastasis was the only independent significant predictors for survival of the patients with PDTC excluding patients with the aggressive variants of PTC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17379963     DOI: 10.1507/endocrj.k06-166

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  25 in total

1.  Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons.

Authors:  Hiroshi Takami; Yasuhiro Ito; Takahiro Okamoto; Akira Yoshida
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

2.  One should not just read what one believes: the nearly irresolvable issue of producing truly objective, evidence-based guidelines for the management of differentiated thyroid cancer.

Authors:  Markus Dietlein; F A Verburg; M Luster; C Reiners; F Pitoia; H Schicha
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05       Impact factor: 9.236

Review 3.  Management of Invasive Differentiated Thyroid Cancer.

Authors:  Iain J Nixon; Ricard Simo; Kate Newbold; Alessandra Rinaldo; Carlos Suarez; Luiz P Kowalski; Carl Silver; Jatin P Shah; Alfio Ferlito
Journal:  Thyroid       Date:  2016-08-23       Impact factor: 6.568

4.  Undetectable Thyroglobulin Levels in Poorly Differentiated Thyroid Carcinoma Patients Free of Macroscopic Disease After Initial Treatment: Are They Useful?

Authors:  Tihana Ibrahimpasic; Ronald Ghossein; Diane L Carlson; Iain J Nixon; Frank L Palmer; Snehal G Patel; Robert M Tuttle; Ashok Shaha; Jatin P Shah; Ian Ganly
Journal:  Ann Surg Oncol       Date:  2015-04-17       Impact factor: 5.344

Review 5.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

6.  Re-evaluation of histopathological factors affecting prognosis of differentiated thyroid carcinoma in an iodine-sufficient country.

Authors:  Iwao Sugitani; Kazuhisa Toda; Noriko Yamamoto; Atsuhiko Sakamoto; Yoshihide Fujimoto
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

7.  Poorly differentiated thyroid carcinoma: 5 years after the 2004 WHO classification of endocrine tumours.

Authors:  Marco Volante; Mauro Papotti
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

Review 8.  The Effectiveness of Radioactive Iodine Remnant Ablation for Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-analysis.

Authors:  Guangfu Hu; Wei Zhu; Weige Yang; Hong Wang; Lei Shen; Hongwei Zhang
Journal:  World J Surg       Date:  2016-01       Impact factor: 3.352

9.  Adequacy of pathology reports of specimens from patients with differentiated thyroid cancer.

Authors:  Ma Luisa Isidro; Gloria Lugo; Olga Fidalgo; Sara García-Arias
Journal:  Endocr Pathol       Date:  2012-12       Impact factor: 3.943

Review 10.  Poorly differentiated thyroid carcinoma: diagnostic features and controversial issues.

Authors:  Marco Volante; Ida Rapa; Mauro Papotti
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.